Related Experiment Video

Updated: Apr 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update

Robert Pirker1

  • 1Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Current Opinion in Oncology
|January 31, 2015
PubMed
Abstract

Insights

Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) show improved survival for select nonsmall cell lung cancer (NSCLC) patients when combined with chemotherapy. Biomarker validation is ongoing to identify optimal patient candidates.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biomarker Research

Background:

  • Epidermal growth factor receptor (EGFR) overexpression is common in nonsmall cell lung cancer (NSCLC).
  • Monoclonal antibodies targeting EGFR are investigated as a strategy to enhance first-line chemotherapy efficacy in NSCLC.

Purpose of the Study:

  • To review updated findings from phase III trials on EGFR monoclonal antibodies in NSCLC treatment.
  • To assess the impact of EGFR blockade on patient outcomes when combined with chemotherapy.

Main Methods:

  • Review of phase III clinical trial data.
  • Analysis of survival outcomes and treatment benefits in NSCLC patients receiving EGFR-targeted therapies.

Main Results:

  • Cetuximab demonstrated improved survival in NSCLC patients with high EGFR expression when added to first-line chemotherapy.
  • Necitumumab, combined with cisplatin and gemcitabine, improved survival in advanced squamous cell NSCLC (SQUIRE trial).
  • The INSPIRE trial was halted due to increased thromboembolic events with necitumumab and chemotherapy in nonsquamous NSCLC.

Conclusions:

  • EGFR monoclonal antibodies can improve outcomes, including survival, in carefully selected advanced NSCLC patients.
  • Ongoing prospective validation of predictive biomarkers is crucial for optimizing EGFR-targeted therapy selection.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K